Acesso livre
Acesso livre

Cardiologia

#ESCCongress – Estudo randomizado | Vacinação precoce contra Influenza após infarto do miocárdio (IM) ou em doença coronariana de alto risco resultou em menor risco de morte por todas as causas, IM ou trombose de stent em comparação com placebo.

2 Set, 2021 | 11:13h

Influenza Vaccination after Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial – Circulation

Comentários:

IAMI: Influenza Vaccine Beneficial for Post-MI Patients – TCTMD

Influenza Vaccination After Myocardial Infarction – IAMI – American College of Cardiology

Flu vaccine after heart attack reduces risk of death – Cardiovascular Business

 

Comentário no Twitter

 

#ESCCongress – Estudo randomizado | Em pacientes em risco de AVC, o rastreamento para fibrilação atrial (FA) usando gravação contínua (loop recorder) resultou em aumento de 3 vezes na detecção de FA e início de anticoagulação, mas não reduziu o risco de AVC ou embolia arterial sistêmica.

2 Set, 2021 | 11:10h

Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial – The Lancet

Comunicado de imprensa: Continuous heart rhythm monitoring and treatment if indicated does not prevent stroke – European Society of Cardiology

Comentário: Atrial Fibrillation Detected by Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-Risk Individuals – LOOP – American College of Cardiology

Conteúdo relacionado: #ESCCongress – RCT: Small benefit from systematic screening for atrial fibrillation in older adults – After a median follow-up of 6.9 y there were fewer events (stroke, embolism, bleeding, and death) in the intervention group (31·9%) vs. control group (33·0%).

#ESCCongress – Estudo randomizado | Em pacientes idosos hipertensos, o tratamento intensivo com pressão arterial sistólica (PAS) alvo entre 110 e 130 mmHg resultou em incidência menor de eventos cardiovasculares do que o tratamento padrão com PAS alvo de 130 a 150 mmHg.

2 Set, 2021 | 11:08h

Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentários:

STEP: Aggressive BP Management in Older Chinese Patients With HTN Improved CV Outcomes vs. Standard Care – American College of Cardiology

STrategy of blood pressure intervention in the Elderly hypertensive Patients – STEP – American College of Cardiology

 

Comentário no Twitter

 

#ESCCongress – M-A | Polipílulas com e sem aspirina reduziram sobremaneira a ocorrência de doença cardiovascular, infarto do miocárdio, AVC, revascularização e morte por causa cardiovascular na prevenção primária de doença cardiovascular.

2 Set, 2021 | 11:06h

Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis – The Lancet (link para o resumo – $ para o texto completo)

Comentário: Combo therapy cuts risk of heart attacks and strokes in half – McMaster University

Conteúdos relacionados:

Opinion: A new important study supports wider use of the polypill

#AHA20 – Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk

Perspective: Are Polypills and Population-based Treatment the Next Big Things?

The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era

Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population

Randomized Trial: Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases

Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology – Global Heart

Perspective: The Polypill and the Long Journey to Major Impact

Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care

#ESCCongress | Diretrizes 2021 da ESC para diagnóstico e tratamento de insuficiência cardíaca aguda e crônica – Inibidores de SGLT2 agora são recomendados para pacientes com insuficiência cardíaca e fração de ejeção reduzida independentemente da presença de diabetes.

30 Ago, 2021 | 13:29h

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC – European Heart Journal

Comunicado de imprensa: ESC Guidelines on heart failure management launched today – European Society of Cardiology

 

Comentário no Twitter

 

#ESCCongress | Diretrizes 2021 da ESC/EACTS para tratamento da doença cardíaca valvar – Nas novas diretrizes, mais pacientes são elegíveis a intervenções cirúrgicas e transcateter, com base não somente nos sintomas, mas também em critérios de imagem.

30 Ago, 2021 | 13:27h

2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) – European Heart Journal

Comunicado de imprensa: European valvular heart disease Guidelines published today – European Society of Cardiology

Resumo: 2021 ESC/EACTS Valvular Heart Disease Guidelines: Key Points – American College of Cardiology

Comentário: Revamped Valve Disease Guideline: Europe Sees Nearly Eye to Eye With U.S. – MedPage Today (necessário cadastro gratuito)

“In line with recent U.S. recommendations, the newest European guidelines favor a wider pool of patients eligible for surgical and transcatheter interventions for valvular heart disease.” (from MedPage Today)

 

Comentários no Twitter

(thread – click for more)

 

#ESCCongress | Diretrizes 2021 da ESC sobre marca-passo cardíaco e terapia de ressincronização cardíaca.

30 Ago, 2021 | 13:26h

2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA) – European Heart Journal

Comunicado de imprensa: ESC Guidelines on cardiac pacing and cardiac resynchronisation therapy launched today – European Society of Cardiology

Ver também: European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing – EP Europace

 

Comentário no Twitter

 

#ESCCongress | Estudo randomizado por clusters: entre pacientes com risco aumentado para AVC, um substituto do sal (75% de cloreto de sódio e 25% de cloreto de potássio) reduziu as taxas de AVC, os eventos cardiovasculares e a morte por qualquer causa.

30 Ago, 2021 | 13:23h

Effect of Salt Substitution on Cardiovascular Events and Death – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comunicado de imprensa: Low-sodium salt prevents stroke – European Society of Cardiology

Comentário: Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD – TCTMD

 

Comentário no Twitter

 

#ESCCongress | Estudo randomizado: inibição de SGLT2 reduziu o risco combinado de morte cardiovascular ou hospitalização em pacientes com insuficiência cardíaca e fração de ejeção preservada, independentemente da presença ou ausência de diabetes.

30 Ago, 2021 | 13:21h

Empagliflozin in Heart Failure with a Preserved Ejection Fraction – New England Journal of Medicine

Comunicado de imprensa: Trial reports first successful results for heart failure with preserved ejection fraction – European Society of Cardiology

Comentário: Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction – EMPEROR-Preserved – American College of Cardiology

 

Comentário no Twitter

 

#ESCCongress | Estudo randomizado: em pacientes com fibrilação atrial submetidos a TARV, o edoxabam foi não inferior a antagonistas de vitamina K quanto à composição do desfecho primário de eventos adversos clínicos, mas resultou em incidência mais alta de sangramento maior.

30 Ago, 2021 | 13:20h

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR – New England Journal of Medicine

Comentários:

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting – TCTMD

ENVISAGE-TAVI AF: Edoxaban vs. Warfarin Following Heart Valve Replacement – American College of Cardiology

Edoxaban vs. Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation–Atrial Fibrillation – ENVISAGE-TAVI AF – American College of Cardiology

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.